title: Enamel matrix derivative is a potent inhibitor of breast cancer cell attachment to bone.
abstract: This study examined whether enamel matrix derivative (EMD) inhibits the adhesion of cancer cells to bone. A typical breast cancer cell line, MCF-7, was used. Conditioned human osteosarcoma cell (Saos-2) medium was used as extracellular bone matrix (ECBM) to measure cell attachment. MCF-7 cells were incubated on ECBM-coated culture plates with or without soluble EMD, Arg-Gly-Asp (RGD) sequence blocking peptides, recombinant bone sialoprotein (rBSP), or specific integrin antibodies, and the attached cells were quantified using toluidine blue staining. EMD markedly reduced the attachment of MCF-7 cells to ECBM in a dose-dependent manner. An RGD peptide (GRGDSP) and recombinant BSP inhibited cell attachment to the same degree as EMD. Similarly, anti-alphavbeta3 integrin antibody strongly reduced cell attachment, whereas anti-alphavbeta5 and anti-beta1 integrin antibodies had less marked effects on cell attachment. These results show that EMD inhibits MCF-7 cell attachment to a bone matrix and that it might be useful as an anti-adhesive agent for breast cancer cells to bone in vivo.
authors.affiliation: Department of Periodontology, Nihon University School of Dentistry, 1-8-13, Kanda Surugadai, Chiyoda-ku, Tokyo 101-8310, Japan.
authors.forename: Tadahiro
authors.initials: T
authors.lastname: Takayama
authors.forename: Naoto
authors.initials: N
authors.lastname: Suzuki
authors.forename: Masataka
authors.initials: M
authors.lastname: Narukawa
authors.forename: Harvey A
authors.initials: HA
authors.lastname: Goldberg
authors.forename: Kichibee
authors.initials: K
authors.lastname: Otsuka
authors.forename: Koichi
authors.initials: K
authors.lastname: Ito
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001857:Bone Matrix / Q000473:pathology; D001859:Bone Neoplasms / Q000556:secondary; D001842:Bone and Bones / Q000473:pathology*; D001943:Breast Neoplasms / Q000473:pathology*; D002448:Cell Adhesion / Q000187:drug effects; D018929:Cell Culture Techniques; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003470:Culture Media; D003746:Dental Enamel Proteins / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005109:Extracellular Matrix / Q000473:pathology; D006801:Humans; D019012:Integrin beta1 / Q000276:immunology; D058574:Integrin-Binding Sialoprotein; D016023:Integrins / Q000276:immunology; D009842:Oligopeptides / Q000494:pharmacology; D019030:Receptors, Vitronectin / Q000276:immunology; D011994:Recombinant Proteins / Q000494:pharmacology; D012795:Sialoglycoproteins / Q000494:pharmacology
chemical_list: D000911:Antibodies, Monoclonal; D003470:Culture Media; D003746:Dental Enamel Proteins; C546871:IBSP protein, human; D019012:Integrin beta1; D058574:Integrin-Binding Sialoprotein; D016023:Integrins; D009842:Oligopeptides; D019030:Receptors, Vitronectin; D011994:Recombinant Proteins; D012795:Sialoglycoproteins; C109069:enamel matrix proteins; C064660:integrin alphaVbeta5; C047981:arginyl-glycyl-aspartic acid